Hormone Receptor Positive Clinical Trials

30 recruitingLast updated: June 18, 2026

There are 30 actively recruiting hormone receptor positive clinical trials across 32 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Los Angeles, California, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Hormone Receptor Positive Trials at a Glance

30 actively recruiting trials for hormone receptor positive are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Dallas. Lead sponsors running hormone receptor positive studies include Fudan University, Radionetics Oncology, and Aminex Therapeutics, Inc..

Browse hormone receptor positive trials by phase

Treatments under study

About Hormone Receptor Positive Clinical Trials

Looking for clinical trials for Hormone Receptor Positive? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone Receptor Positive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone Receptor Positive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 1Phase 2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.92 enrolled12 locationsNCT07287917
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2

VS-6766+Abema+Fulv in Met HR+/HER- BC

Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks63 enrolled3 locationsNCT05608252
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor+1 more
SOLTI Breast Cancer Research Group96 enrolled15 locationsNCT05982093
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Head and Neck CancerNon-small Cell Lung CancerTriple Negative Breast Cancer(TNBC)+4 more
Aktis Oncology, Inc.150 enrolled9 locationsNCT07020117
Recruiting
Not Applicable

A Study of the TheraBionic P1 Device in Breast Cancer

HER2-negative Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Barbara Ann Karmanos Cancer Institute24 enrolled8 locationsNCT07218432
Recruiting
Phase 1Phase 2

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine152 enrolled3 locationsNCT06374459
Recruiting
Phase 1

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer
Radionetics Oncology62 enrolled7 locationsNCT07121244
Recruiting
Phase 1Phase 2

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Recruiting
Phase 1Phase 2

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Metastatic Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Ellipses Pharma95 enrolled14 locationsNCT05573126
Recruiting
Not Applicable

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+3 more
Brigham and Women's Hospital214 enrolled1 locationNCT04030507
Recruiting
Not Applicable

Ablation Compare With Surgery for Early Breast Cancer

Breast CancerAblationEarly Stage+1 more
Peking University People's Hospital264 enrolled1 locationNCT07484087
Recruiting
Phase 1

Study of 68Ga-R10602

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma
Radionetics Oncology36 enrolled6 locationsNCT06745804